6533b85ffe1ef96bd12c0f68

RESEARCH PRODUCT

A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.

Maria Teresa Kong-sanchezMarkus MoehlerJin Won KimJae Yong ChoYung-jue BangAgnes BaloghYeul Hong KimMaria Di BartolomeoKensei YamaguchiJaffer A. Ajani

subject

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFirst linemedicine.medical_treatmentGastro esophageal junctionLocally advancedIpilimumab03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineIn patientChemotherapybusiness.industryCancermedicine.diseaseSurgery030104 developmental biologyOncology030220 oncology & carcinogenesisOpen labelbusinessmedicine.drug

description

4011Background: Pts with advanced gastric cancer have a poor prognosis with median overall survival (OS) of ~1 yr. Ipi is a monoclonal antibody that enhances T-cell activation and T-effector cell t...

https://doi.org/10.1200/jco.2016.34.15_suppl.4011